10 completed, 4 withdrawn, 3 terminated, 3 unknown. 21 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 10, Withdrawn 4, Terminated 3, Unknown 3, Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Hemolysis: new trials by email Literature Review of Hemolysis trials Research Report on Hemolysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders Ravulizumab - Preeclampsia | Phase 2 | Recruiting | Mayo Clinic | 14 | 2027-04-01 | 2026-10-22 |
| Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease - Sickle Cell Disease | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 30 | 2023-03-22 | 2023-09-21 |
| A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease Etavopivat tablets - Sickle Cell Disease, Thalassemia | Phase 2 | Completed | Forma Therapeutics, Inc. | 53 | 2022-03-28 | 2025-12-16 |
| A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH CAN106 20 mg/kg, CAN106 40 mg/kg, CAN106 80 mg/kg - PNH, Hemolysis | Phase 1 / Phase 2 | Unknown | CARE Pharma Shanghai Ltd. | 78 | 2022-03-25 | 2022-09-14 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP KZR-616 - Autoimmune Hemolytic Anemia, Immune Thrombocytopenia | Phase 2 | Withdrawn | Kezar Life Sciences, Inc. | 2020-07-01 | 2020-08-07 | |
| Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy ALXN2050 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 29 | 2019-12-16 | 2024-11-20 |
| Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria LNP023 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Novartis Pharmaceuticals | 13 | 2019-04-05 | 2024-06-18 |
| Effects of Nitric Oxide on the Endothelium During Hemolysis. Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection - Endothelial Dysfunction, Hemolysis Intravascular | Phase 2 | Withdrawn | Massachusetts General Hospital | 2018-12-05 | 2025-12-02 | |
| A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH Pegcetacoplan - PNH | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 4 | 2018-08-16 | 2020-12-22 |
| Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) iptacopan, Standard of Care - Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis | Phase 2 | Completed | Novartis Pharmaceuticals | 16 | 2018-04-09 | 2024-06-12 |
| A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Cemdisiran - Atypical Hemolytic Uremic Syndrome | Phase 2 | Withdrawn | Alnylam Pharmaceuticals | 2017-09-19 | 2018-10-01 | |
| Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion Nitric Oxide - Hypertension, Pulmonary, Hemolysis | Phase 2 | Withdrawn | Massachusetts General Hospital | 2016-03-01 | 2016-03-18 | |
| Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease Bendamustine, Rituximab - Cold Agglutinin Disease, Autoimmune Hemolytic Anemia | Phase 2 | Completed | Helse Fonna | 43 | 2013-01-01 | 2017-01-09 |
| Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. levamisole, Prednisone - Anemia, Anemia, Hemolytic | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 100 | 2012-04-01 | 2012-04-19 |
| Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Conditioning Regimen with Bone Marrow Transplant - Sickle Cell Disease | Phase 2 | Completed | Emory University | 22 | 2012-03-01 | 2017-11-21 |
| Therapy of Chronic Cold Agglutinin Disease With Eculizumab Eculizumab - Cold Agglutinin Disease | Phase 2 | Completed | University Hospital, Essen | 13 | 2011-01-01 | 2017-07-19 |
| Study of Albumin to Reduce Inflammation Following Surgery 20% Human albumin solution, Gelofusin - Systemic Inflammatory Response Syndrome, Cardiopulmonary Bypass | Phase 2 | Terminated | Imperial College London | 232 | 2008-12-01 | 2014-05-28 |
| A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia Stannsoporfin, Placebo, PhotoTherapy (as needed) - Hyperbilirubinemia, Neonatal | Phase 2 | Terminated | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 58 | 2008-08-01 | 2019-10-30 |
| Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Alemtuzumab, Rituximab - Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune | Phase 2 / Phase 3 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 19 | 2008-08-01 | 2010-08-30 |
| S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease - Chronic Hepatitis C | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 24 | 2007-05-01 | 2013-07-05 |
Showing 20 of 21. Sign in to see all of them.
Anemia (8) · Anemia, Hemolytic, Autoimmune (6) · Hematologic Diseases (5) · Hemoglobinuria, Paroxysmal (4) · Anemia, Sickle Cell (3) · Anemia, Hemolytic (2) · Genetic Diseases, Inborn (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Thrombocytopenia (2) · Atypical Hemolytic Uremic Syndrome (1) · Autoimmune Diseases (1) · Cardiovascular Diseases (1) · Hemoglobinopathies (1) · Hemoglobinuria (1)
Pathological Conditions, Signs and Symptoms (21) · Pathologic Processes (20) · Hemic and Lymphatic Diseases (14) · Anemia, Hemolytic (12) · Hematologic Diseases (9) · Anemia (6) · Autoimmune Diseases (5) · Immune System Diseases (5) · Bone Marrow Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Myelodysplastic Syndromes (4) · Anemia, Hemolytic, Congenital (3) · Blood Platelet Disorders (3) · Cytopenia (3) · Female Urogenital Diseases and Pregnancy Complications (3)
Rituximab (3) · Nitric Oxide (2) · fludarabine (2) · iptacopan (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Hemoglobin, Sickle (1) · KZR-616 (1) · Levamisole (1) · Phototherapy (1) · Prednisone (1) · Ribavirin (1)
Massachusetts General Hospital (2) · Novartis Pharmaceuticals (2) · Alexion Pharmaceuticals, Inc. (1) · Alnylam Pharmaceuticals (1) · Apellis Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · CARE Pharma Shanghai Ltd. (1) · Emory University (1) · Forma Therapeutics, Inc. (1) · Helse Fonna (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Imperial College London (1) · InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Kezar Life Sciences, Inc. (1)
United States (8) · Italy (4) · Canada (3) · United Kingdom (3) · China (2) · France (2) · Germany (2) · Norway (2) · Poland (2) · Russia (2) · Serbia (2) · South Korea (2) · Spain (2) · Australia (1) · Bosnia and Herzegovina (1)
Geir E Tjonnfjord, MD, PhD (2) · Sigbjorn Berentsen, MD, PhD (2) · Alexander Roeth, MD (1) · Bing Han, MD (1) · David Gomez-Almaguer, MD (1) · Elling Ulvestad, MD, PhD (1) · Federico Grossi, MD, PhD (1) · Henrik Birgens, MD, PhD (1) · Hongzhong Liu, MMed (1) · Jay Hoofnagle, MD (1) · Lakshmanan Krishnamurti, MD (1) · Lorenzo Berra, MD (1)
PMID 20634373, PMID 20841509, PMID 20854821, PMID 28533306, PMID 30291112, PMID 33765419, PMID 35561315, PMID 35869170, PMID 41124654, PMID 41603130
2009 (2), 2017 (1), 2019 (1), R34HL108761 (1)